We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of CM Life Sciences, Inc. (“CMLF” or the “Company”) (NASDAQ: CMLF) in connection with the Company’s proposed merger with Sema4 (“Sema4”), a privately-held integrated genomic and clinical data company.  Under the terms of the merger agreement, CMLF will acquire Sema4 through a reverse merger that will result in Sema4 becoming a becoming a public company traded on the Nasdaq Global Market.  The transaction values Sema4 at an enterprise value of approximately $2 billion.

WeissLaw LLP is investigating whether CMLF’s board acted in the best interest of CMLF’s public shareholders in agreeing to the proposed transaction, whether the board was fully informed as to the valuation of Sema4, and whether all information regarding the process undertaken by the board and the valuation of the transaction will be fully and fairly disclosed to CMLF public shareholders. WeissLaw LLP has litigated hundreds of stockholder class and derivative actions for violations of corporate and fiduciary duties.  We have recovered over a billion dollars for defrauded clients and obtained important corporate governance relief in many of these cases.  If you have information or would like legal advice concerning possible corporate wrongdoing (including insider trading, waste of corporate assets, accounting fraud, or materially misleading information), consumer fraud (including false advertising, defective products, or other deceptive business practices), or anti-trust violations, please email us at stockinfo@weisslawllp.com